Kodiak Sciences Inc.

NASDAQ:KOD

9.25 (USD) • At close December 23, 2024
Bedrijfsnaam Kodiak Sciences Inc.
Symbool KOD
Munteenheid USD
Prijs 9.25
Beurswaarde 486,770,150
Dividendpercentage 0%
52-weken bereik 2.19 - 11.6
Industrie Biotechnology
Sector Healthcare
CEO Dr. Victor Perlroth M.D.
Website https://kodiak.com

An error occurred while fetching data.

Over Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment

Vergelijkbare Aandelen

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

76.79 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

4.77 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

62.82 USD

Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc.

OTLK

1.42 USD

Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation

ABUS

3.19 USD

Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc.

MNMD

7.08 USD

Esperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc.

ESPR

2.24 USD

Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

TYRA

14.25 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)